WuXi Biologics receives EMA approval for five facilities in China

WuXi Biologics (2269.HK), a major Chinese contract research, development, and manufacturing organization (CDMO), has had four facilities certified by the European Medicines Agency.

The four manufacturing sites, as well as the Suzhou Biosafety Testing Center, have received Good Manufacturing Practice (GMP) certificates following inspections from EMA staff.

All facilities have previously received approval from the EMA and other major regulatory bodies for developing various biologic therapeutics.